Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01129531 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 294
- Enrollment target
NCT01129531 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 294 participants.
The verdict
NCT01129531, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 294 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of AGN-214868 in patients with postherpetic neuralgia (PHN) - nerve pain.
Interventions
- DRUG AGN-214868
- DRUG Placebo to AGN-214868
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01129531
The ClinicalTrials.gov registry entry for NCT01129531 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AGN-214868 is the first listed.
NCT01129531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01129531 about?
NCT01129531 is a clinical study titled "A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia". This study will evaluate the safety and efficacy of AGN-214868 in patients with postherpetic neuralgia (PHN) - nerve pain.
What is the current status of trial NCT01129531?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 294 participants. The study started on 2010-06. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01129531?
The interventions under investigation include: AGN-214868 (DRUG), Placebo to AGN-214868 (DRUG).
Who is sponsoring clinical trial NCT01129531?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.